FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309961332> ?p ?o ?g. }

• W4309961332 abstract "Abstract Background Mobilisation and exercise intervention in general are safe and feasible in critically ill patients. For patients requiring catecholamines, however, doses of norepinephrine safe for mobilisation in the intensive care unit (ICU) are not defined. This study aimed to describe mobilisation practice in our hospital and identify doses of norepinephrine that allowed a safe mobilisation. Methods We conducted a retrospective single-centre cohort study of 16 ICUs at a university hospital in Germany with patients admitted between March 2018 and November 2021. Data were collected from our patient data management system. We analysed the effect of norepinephrine on level (ICU Mobility Scale) and frequency (units per day) of mobilisation, early mobilisation (within 72 h of ICU admission), mortality, and rate of adverse events. Data were extracted from free-text mobilisation entries using supervised machine learning (support vector machine). Statistical analyses were done using (generalised) linear (mixed-effect) models, as well as chi-square tests and ANOVAs. Results A total of 12,462 patients were analysed in this study. They received a total of 59,415 mobilisation units. Of these patients, 842 (6.8%) received mobilisation under continuous norepinephrine administration. Norepinephrine administration was negatively associated with the frequency of mobilisation (adjusted difference -0.07 mobilisations per day; 95% CI − 0.09, − 0.05; p ≤ 0.001) and early mobilisation (adjusted OR 0.83; 95% CI 0.76, 0.90; p ≤ 0.001), while a higher norepinephrine dose corresponded to a lower chance to be mobilised out-of-bed (adjusted OR 0.01; 95% CI 0.00, 0.04; p ≤ 0.001). Mobilisation with norepinephrine did not significantly affect mortality ( p > 0.1). Higher compared to lower doses of norepinephrine did not lead to a significant increase in adverse events in our practice ( p > 0.1). We identified that mobilisation was safe with up to 0.20 µg/kg/min norepinephrine for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0–1) mobilisation. Conclusions Mobilisation with norepinephrine can be done safely when considering the status of the patient and safety guidelines. We demonstrated that safe mobilisation was possible with norepinephrine doses up to 0.20 µg/kg/min for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0–1) mobilisation." @default.
• W4309961332 created "2022-11-30" @default.
• W4309961332 creator A5010028375 @default.
• W4309961332 creator A5019636868 @default.
• W4309961332 creator A5031763874 @default.
• W4309961332 creator A5032144974 @default.
• W4309961332 creator A5035934454 @default.
• W4309961332 creator A5038286239 @default.
• W4309961332 creator A5040456004 @default.
• W4309961332 creator A5048444402 @default.
• W4309961332 creator A5057254396 @default.
• W4309961332 creator A5058637359 @default.
• W4309961332 creator A5063781065 @default.
• W4309961332 creator A5078398049 @default.
• W4309961332 creator A5091792060 @default.
• W4309961332 date "2022-11-25" @default.
• W4309961332 modified "2023-10-18" @default.
• W4309961332 title "Mobilisation of critically ill patients receiving norepinephrine: a retrospective cohort study" @default.
• W4309961332 cites W1898928487 @default.
• W4309961332 cites W1951724000 @default.
• W4309961332 cites W2061326496 @default.
• W4309961332 cites W2071637551 @default.
• W4309961332 cites W2077789801 @default.
• W4309961332 cites W2099066338 @default.
• W4309961332 cites W2104566817 @default.
• W4309961332 cites W2118831668 @default.
• W4309961332 cites W2149943383 @default.
• W4309961332 cites W2157889190 @default.
• W4309961332 cites W2258512496 @default.
• W4309961332 cites W2306989133 @default.
• W4309961332 cites W2336721585 @default.
• W4309961332 cites W2514567689 @default.
• W4309961332 cites W2518691166 @default.
• W4309961332 cites W2525291310 @default.
• W4309961332 cites W2525872553 @default.
• W4309961332 cites W2530201145 @default.
• W4309961332 cites W2774201559 @default.
• W4309961332 cites W2782220391 @default.
• W4309961332 cites W2807293735 @default.
• W4309961332 cites W2895553377 @default.
• W4309961332 cites W2914331156 @default.
• W4309961332 cites W2920955762 @default.
• W4309961332 cites W2969481210 @default.
• W4309961332 cites W2979607045 @default.
• W4309961332 cites W2980962206 @default.
• W4309961332 cites W2981957551 @default.
• W4309961332 cites W3016555942 @default.
• W4309961332 cites W3021678116 @default.
• W4309961332 cites W3084002895 @default.
• W4309961332 cites W3092833835 @default.
• W4309961332 cites W3119052096 @default.
• W4309961332 cites W3160232512 @default.
• W4309961332 cites W4293242440 @default.
• W4309961332 cites W4305072181 @default.
• W4309961332 cites W4307291554 @default.
• W4309961332 doi "https://doi.org/10.1186/s13054-022-04245-0" @default.
• W4309961332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36434724" @default.
• W4309961332 hasPublicationYear "2022" @default.
• W4309961332 type Work @default.
• W4309961332 citedByCount "3" @default.
• W4309961332 countsByYear W43099613322023 @default.
• W4309961332 crossrefType "journal-article" @default.
• W4309961332 hasAuthorship W4309961332A5010028375 @default.
• W4309961332 hasAuthorship W4309961332A5019636868 @default.
• W4309961332 hasAuthorship W4309961332A5031763874 @default.
• W4309961332 hasAuthorship W4309961332A5032144974 @default.
• W4309961332 hasAuthorship W4309961332A5035934454 @default.
• W4309961332 hasAuthorship W4309961332A5038286239 @default.
• W4309961332 hasAuthorship W4309961332A5040456004 @default.
• W4309961332 hasAuthorship W4309961332A5048444402 @default.
• W4309961332 hasAuthorship W4309961332A5057254396 @default.
• W4309961332 hasAuthorship W4309961332A5058637359 @default.
• W4309961332 hasAuthorship W4309961332A5063781065 @default.
• W4309961332 hasAuthorship W4309961332A5078398049 @default.
• W4309961332 hasAuthorship W4309961332A5091792060 @default.
• W4309961332 hasBestOaLocation W43099613321 @default.
• W4309961332 hasConcept C126322002 @default.
• W4309961332 hasConcept C167135981 @default.
• W4309961332 hasConcept C177713679 @default.
• W4309961332 hasConcept C194828623 @default.
• W4309961332 hasConcept C197934379 @default.
• W4309961332 hasConcept C201903717 @default.
• W4309961332 hasConcept C2776376669 @default.
• W4309961332 hasConcept C2778514916 @default.
• W4309961332 hasConcept C2987404301 @default.
• W4309961332 hasConcept C2991859549 @default.
• W4309961332 hasConcept C42219234 @default.
• W4309961332 hasConcept C513476851 @default.
• W4309961332 hasConcept C71924100 @default.
• W4309961332 hasConcept C72563966 @default.
• W4309961332 hasConceptScore W4309961332C126322002 @default.
• W4309961332 hasConceptScore W4309961332C167135981 @default.
• W4309961332 hasConceptScore W4309961332C177713679 @default.
• W4309961332 hasConceptScore W4309961332C194828623 @default.
• W4309961332 hasConceptScore W4309961332C197934379 @default.
• W4309961332 hasConceptScore W4309961332C201903717 @default.
• W4309961332 hasConceptScore W4309961332C2776376669 @default.
• W4309961332 hasConceptScore W4309961332C2778514916 @default.
• W4309961332 hasConceptScore W4309961332C2987404301 @default.
• W4309961332 hasConceptScore W4309961332C2991859549 @default.

• next